Systemic Lupus Erythematosus – What are the Recommendations for the Treatment of Skin Manifestations from the Perspective of a Rheumatologist?
Authors:
H. Ciferská
Authors‘ workplace:
Revmatologický ústav, Praha a Revmatologická klinika, 1. LF UK a VFN, Praha
Published in:
Čes-slov Derm, 101, 2026, No. 3, p. 119-130
Category:
Reviews (Continuing Medical Education)
Overview
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease with heterogeneous manifestations ranging from mild skin-joint forms associated with immunological abnormalities to life-threatening conditions with rapid progression of organ involvement. Current recommendations for therapy based on multinational European and American guidelines emphasize combined glucocorticoid-sparing immunosuppressive therapy including biological therapy. The recommendations consider not only the severity of organ manifestations, but also their specificities. The goal of therapy is to achieve remission, or at least low disease activity, prevent disease flare-ups and limit the accumulation of organ damage and their early detection. Prevention of comorbidities and their early detection has become another priority. Skin involvement in SLE is both specific (acute, subacute and chronic lupus) and non-specific. Skin manifestations are rarely life-threatening, but can significantly worsen the quality of life of patients.
Keywords:
Systemic lupus erythematosus – biological treatment – skin manifestations
Sources
1. ALBRECHT, J., TAYLOR, L,. BERLIN, J. A. et al The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol., 2005, 125(5), p. 889–894.
2. ARINGER, M., COSTENBADER, K., DAIKH, D. et al 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis., 2019, 78(9), p. 1151–1159.
3. FANOURIAKIS, A., TZIOLOS, N., BERTSIAS, G., BOUMPAS, D. T. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis., 2021, 80(1), p. 14–25
4. FANOURIAKIS, A., KOSTOPOULOU, M., ANDERSEN, J. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis., 2024, 2, 83(1), p. 15–29.
5. GILLIAM, J. N., SONTHEIMER, R. D. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol., 1981, 4, p. 471–475.
6. HOI, A., IGEL, T., MOK, C. C., ARNAUD, L. Systemic lupus erythematosus. Lancet, 2024, 25, 403(10441), p. 2326–2338.
7. LEE, H. J., SINHA, A. A. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoimmunity, 2006, 39, p. 433.
8. MARZANO, A. V., VEZZOLI, P., CROSTI, C. Drug-induced lupus: an update on its dermatologic aspects. Lupus, 2009, 18(11), p. 935–940.
9. PETERSEN, M. P., MÖLLER, S., BYGUM, A. et al. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus, 2018, 27(9), p.1424–1430.
10. SAMMARITANO, L.R., ASKANASE, A., BERMAS, B. L. et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken), 2025. doi: 10.1002/acr.25690. Epub ahead of print.
11. SIEGEL, M., LEE, L.W. Neonatal Skin Emergencies. Pediatr Ann., 2019, 48(1), p. e36–e42.
12. SONTHEIMER, R. D. The lesions of cutaneous lupus erythematosus – a review and personal perspective on nomenclature and classification of cutaneous manifestations of lupus erythematosus. Lupus, 1997, 6, p. 84–95.
13. STULL, C., SPROW, G., WERTH, V. P. Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. J Rheumatol., 2023, 50(1), p. 27–35.
14. UVA L, MIGUEL, D., PINHEIRO, C., FREITAS, J. P., MARQUES GOMES, M., FILIPE P. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis., 2012, 2012, p. 834291.
15. VALE, E.C.S.D., GARCIA, L.C. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. An Bras Dermatol., 2023, 98(3), p. 355–372.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2026 Issue 3
Most read in this issue
- Systemic Lupus Erythematosus – What are the Recommendations for the Treatment of Skin Manifestations from the Perspective of a Rheumatologist?
- Pyoderma gangrenosum: Three Cases Report and Literature Review
- DERMATOLOGY FUNDAMENTALS
- Odborné akce 2026